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Abstract
Background: Motor deficits are a critical component of the clinical characteristics of patients with spinocerebellar ataxia
type 2. However, there is no current information on the preclinical manifestation of those motor deficits in presymptomatic
gene carriers. To further understand and characterize the onset of the clinical manifestation in this disease, we tested
presymptomatic spinocerebellar ataxia type 2 gene carriers, and volunteers, in a task that evaluates their motor
performance and their motor learning capabilities.
Methods and Findings: 28 presymptomatic spinocerebellar ataxia type 2 gene carriers and an equal number of control
volunteers matched for age and gender participated in the study. Both groups were tested in a prism adaptation task
known to be sensible to both motor performance and visuomotor learning deficits. Our results clearly show that although
motor learning capabilities are intact, motor performance deficits are present even years before the clinical manifestation of
the disease start.
Conclusions: The results show a clear deficit in motor performance that can be detected years before the clinical onset of
the disease. This motor performance deficit appears before any motor learning or clinical manifestations of the disease.
These observations identify the performance coefficient as an objective and quantitative physiological biomarker that could
be useful to assess the efficiency of different therapeutic agents.
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Introduction
Spinocerebellar ataxia type 2 (SCA2) is a genetic-based disorder
with primarysymptomsof progressive gait ataxia, diminished saccade
velocity [1], poor coordination of speech musculature (dysarthria),
olfactorydeficits [2,3] and absence of neurological reflexes such as the
knee jerk reaction (areflexia) [4–6]. This polyglutamine (PolyQ)
disorder produces severe degeneration of pontine nuclei, inferior
olives, and Purkinje cells in the cerebellum [7,8].
A general characteristic of hereditary neurodegenerative
diseases is that clinical symptoms not necessarily emerge from
birth, but can appear throughout different life stages. The specific
age at which overt clinical manifestations appear is in close
relationship to the individual repeat length [9]. Nevertheless,
different studies have demonstrated that in several neurodegener-
ative diseases, specific deficiencies can be detected in presymp-
tomatic gene carrier individuals. For example, deficits has been
found in clinically presymptomatic familial autosomic dominant
Alzheimer [10], or in clinically presymptomatic Huntington gene
carriers individuals, who show deficits in motor control [11–14],
learning of motor sequences [15], and other non-motor functions,
like memory and executive functions [16–18], visuospatial
processing [19] and olfaction [20]. These kinds of deficits are
usually detected only through specialized testing.
Early symptoms reported by SCA2 patients appearing before
gait ataxia, which is the most notorious clinical deficit, include
dysarthria, problems with hand writing, and sleep disturbances
[21]. However, to our knowledge (based on public Medline and
scholar Google searches) there are only two studies that have
found preclinical deficits in SCA2 gene carriers. Those reports
show brisk deep-tendon reflexes [22] and electrophysiological
alterations in sensory nerve conduction, and somatosensory and
auditory evoked potentials [23].
To understand the progressive changes taking place before the
onset of the clinical manifestations in SCA2, we evaluated the
performance and visuomotor learning capabilities of presymptomatic
gene carrier individuals. For this purpose, we used a task sensible to
both, SCA2 gene mutation [24] and cerebellar damage [25].
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Subjects
Twenty eight clinically presymptomatic SCA2 gene carriers (11
male and 17 female patients) with ages ranging from 27 to 63 years
(mean, 39.6; standard deviation (S.D)69.1), probable age of onset
from 28 to 63 years (mean, 45; S.D.62), and polyglutamine repeat
sizes from 32 to 41 repetitions (mean, 36.6; S.D.62.6) were
admitted to the Center for the Research and Rehabilitation of
Hereditary Ataxias in Holguı ´n for this study (see Table 1 for
individual demographic information). The diagnosis of SCA2 was
based on genealogical descent from the founder population, and
on molecular genetic determination of the repeat expansions. The
clinical assessment was conducted using a standard neurological
exam [26] and the Scale for the assessment and rating of ataxia
(SARA) [27]. This scale comprise eight items: evaluation of gait
(score 0–8), stance (score 0–6), sitting (score 0–4) and speech (score
0–6), and four tests assessing limb kinetic function (finger chase
[score 0–4], fast alternating hand movements [score 0–4], finger-
nose-finger test [score 0–4] and heel-shin test [score 0–4])
evaluates the core clinical symptoms in ataxia diseases [27].
The predicted age at clinical onset (AACO) correlating to each
polyglutamine expansion size was calculated after the formula
originally published in the article describing the SCA2 mutation:
[AACO]=1171.583 * e
(20.091* polyglutamine expantion size) [9]. A group
o f2 8a g ea n dg e n d e r - m a t c h e du n p a i dh e a l t h ya d u l tv o l u n t e e r sw i t h
no history of neurological injury or psychiatry disease from Holguı ´n
province (11 male and 17 female subjects) with ages ranging from 27
to 61 years (means, 38; S.D.69.6) served as controls (CON). The
control group also had the same clinical assessment and SARA
evaluations as the SCA2 patients. Subjects with previous history of
any other major disorder that could affect visuomotor performance
were not entered into the study. All SCA2 patients and controls were
right handed. The study plan was approved by the Center for the
Research and Rehabilitation of Hereditary Ataxias in Holguı ´na n d
National Autonomous University of Mexico ethics committees before
recruitment of participants started. Therefore, all the experimenta-
tion procedures followed were in accordance with the ethical
standards of both committees. In addition, all subjects signed an
informed consent prior to the experiments in accordance with the
Helsinki Declaration (Council for International Organizations of
Medical Sciences and World Health Organization, 2002).
Table 1. Presymptomatic SCA2 gene carriers demographic information.
Ss Age Gender Lineage
Normal allele
repetitions
Mutated allele
repetitions
Predicted
AACO
Years to
AACO
SARA
score
1 41 f Paternal 22 36 44.26 3.00 0
2 31 f Paternal 22 32 63.70 32.70 1
3 63 f Maternal 22 34 53.10 29.90 0
4 61 f Maternal 22 34 53.10 27.90 0
5 27 f Maternal 22 35 30.76 3.76 0
6 47 f Paternal 22 32 63.70 16.70 0
7 34 f Paternal 22 34 53.10 19.10 0
8 31 f Paternal 24 39 33.69 2.69 0
9 38 f Maternal 29 34 33.69 24.31 0
10 37 f Paternal 29 37 40.41 3.41 0
11 44 f Maternal 24 39 48.48 4.48 0
12 32 f Paternal 22 38 36.90 4.90 1
13 40 f Paternal 34 39 53.10 13.10 0
14 32 f Paternal 22 33 58.15 26.15 0
15 37 f Maternal 22 36 44.26 7.26 1
16 42 f Paternal 22 38 36.90 25.10 0
17 39 f Paternal 22 35 48.48 9.48 0
18 35 m Paternal 22 35 48.48 13.48 0
19 39 m Maternal 23 38 48.48 9.48 0
20 41 m Maternal 22 36 44.26 3.26 1
21 41 m Maternal 24 38 36.90 24.10 0
22 35 m Paternal 22 36 44.26 9.26 0
23 34 m Maternal 22 41 28.08 25.92 0
24 50 m Paternal 22 35 48.48 21.52 1
25 58 m Maternal 22 34 53.10 24.90 0
26 32 m Paternal 22 36 44.26 12.26 0
27 41 m Maternal 22 41 28.08 212.92 0
28 28 m Paternal 23 41 28.08 0.08 2
AACO is the probable age at clinical onset. SARA is the Scale for the assessment and rating of ataxia.
doi:10.1371/journal.pone.0005398.t001
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A detailed description of the procedure and our modifications
can be found elsewhere [25,28]. Subjects threw clay balls (weight:
10 g) at a 12-cm612-cm cross drawn on a large sheet of parcel
paper centered at shoulder level and placed 2 m away in front of
them. Subjects were instructed to make each toss overhand during
the whole experiment, to use the right hand, and to throw the balls
to the location where they saw the target. The subjects had an
unobstructed view of the target during the entire session. Subjects
stood, the head was unrestrained, and no directions were given
about trunk, shoulder or head/neck posture [25]. However, they
were not allowed to look down at their hand as they collected the
next ball from a tray located next to them. Subjects were asked to
throw at their own pace, so they were free to take rests if they felt
tired. If such event occurred, they were asked to remain still as
possible with their eyes closed.
The experiment had three conditions. Under each condition the
subjects threw 26 balls. During the baseline condition (PRE)
subjects did not wear prisms. After finishing the baseline condition
subjects were tested in the PRISM condition, where they wore 30
diopter Fresnel 3 M Press-on plastic lenses (3 M Health Care,
Specialties Division, St. Paul, MN, USA) that produce a light
refraction to the right. Once that condition was finished, subjects
had the prisms removed and started the POS condition where they
continued throwing balls. The location of the balls impacts were
plotted sequentially by trial number (abscissa) versus horizontal
displacement (in centimeters) from a vertical line passing through
the target centre (ordinate). Impacts to the left of the target were
plotted as negative values and impacts to the right were plotted as
positive values. The three experimental conditions were carried
out consecutively after the donning or doffing of the prisms was
completed.
Three additional measures were calculated from the collected
data of both experiments. First, a motor performance coefficient
(PC) (or called variable errors [24,25]) was calculated from the
baseline phase. To obtain the PC, the horizontal errors (distance
from each impact location to a vertical line passing through the
target) of the PRE trials were measured. The PC is the standard
deviation obtained from these errors [25]. Second, an adaptation
magnitude was obtained by subtracting the horizontal distance to
the target on the final throw from that on the initial throw while
wearing the prisms (PRISM condition). Third, an aftereffect
measure was defined as the ball’s impact horizontal distance to the
target on the first throw after removing the prisms.
Results
Predicted time to clinical manifestations
Time to clinical manifestation was calculated as years remaining
from subjects’ current age at the time of testing to the calculated
age of onset accordingly to their polyglutamine expansion size.
The analysis suggested that the mean time to start clinical
manifestations for this specific population of presymptomatic
subjects was 5.9762.21 years.
Ataxia score
All the pre-SCA2 gene carriers had a SARA score between 0
and 2 (mean 0.2360.49 SDM), of the possible maximum score of
40. Since previous studies have found normal subjects showing
scores as high as 7, all the pre-SCA2 participants could not be
differentiated from normal volunteers based on the SARA score,
confirming their clinically presymptomatic status [27]. In the
present study all the control volunteers had a score between 0 and
0.5, so they did not show any deficit measured with the SARA.
Motor performance coefficient
Measurements from the throws made during the baseline
condition without visual perturbation were used to evaluate motor
performance. Motor performance coefficients for each group were
as follows: CON=4.7760.26 s.e.m., and pre-SCA2=6.260.45
s.e.m. (Figure 1). A Kolmogorov-Smirnov normality test shows
that although the data distribution for the control group passed
(p=0.066) the test, the pre-SCA 2 group failed it (p,0.05).
Therefore a Mann-Whitney rank sum test was used to compare
between both groups. The results showed a significant difference
between controls and patients (U=541, T=649, n=28, p=0.01).
Adaptation
The adaptation measures obtained during the prism phase were
as follows: CON=44.962.2, and preSCA2=42.162.8 (Figure 2
Left). A Kolmogorov-Smirnov normality test showed that both
groups data passed the normality (p=0.794) and equal variance
tests (p=0.195). A two-tailed Student’s t test was performed to
look for adaptation differences between control subjects and
presymptomatic gene SCA2 carriers. The analysis showed no
differences between groups (t=0.7, d.f.=54, p=0.43) (Figure 2A).
To analyze de adaptation rate, a two way repeated measures
ANOVA was used. The conditions were groups (Controls and pre-
SCA2) and throws. The analysis showed that there were no
differences between both groups (d.f.=1, F=1.156, p=0.287),
but, as expected, there were significant differences among throws
(d.f.=25, F 77.213, p,0.01). However, the analysis also showed
that there were no significant interactions between groups and
throws (d,f,=25, F=1.151, p=0.276) (Figure 2B).
Aftereffects
The aftereffect absolute values were as follows:
CON=19.662.2 s.e.m., preSCA2=2062.2 s.e.m. (Figure 2A).
A Kolmogorov-Smirnov normality test showed that both groups
Figure 1. Motor performance coefficient of the control (black)
and the pre-SCA2 (grey) groups. Error bars are SEM. *=p,0.01.
doi:10.1371/journal.pone.0005398.g001
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(p=0.874). A two-tailed Student’s t test was performed for
analyzing possible aftereffect differences between control and
presymptomatic gene SCA2 carriers. The analysis showed no
differences between groups (t=0.14, d.f.=54, p=0.88).
The motor deficit and time to start clinical manifestations
in SCA2 gene carriers
Since the experimental results show motor deficits in the clinical
presymptomatic SCA2 gene carriers, an important question was if
there is a correlation between those deficits and the years
remaining to reach the predicted age at clinical onset. A Pearson
product moment correlation showed a significant correlation
between those two variables (CC=0.437, p=0.02).
Discussion
The present results suggest that clinically presymptomatic SCA2
gene carriers show an early motor deficit manifested as
deterioration in their motor performance coefficient. This deficit
can be detected on average even five years before the clinical
manifestations onset. The neural deterioration causing the motor
deficit is not enough, however, to disrupt neither their motor
learning nor the measures obtained from the SARA scale.
The motor performance deficit in presymptomatic individuals
could be explained if the neurodegeneration starts years before the
clinical onset. For example, it has been established that SCA2
asymptomatic individuals show cerebellar hypometabolism and
fourth ventricle dilatation even years before clinical manifestation
of the disease [29]. Hence, it would be interesting to test if the
motor performance deficit could be evidence of an incipient
neurodegeneration, since it shows a positive correlation with the
years remaining to reach the predicted age at clinical onset.
The task used here can measure both, motor performance and
visuomotor learning. Initial findings suggest that these two
variables are independent, since they can be dissociated in patients
with different cerebellar lesions [25]. Therefore, it could be
possible that SCA2 initially affects structures important for motor
performance but not motor learning. On the other hand,
compensatory mechanisms have been found during the course of
neurodegenerative diseases, as suggested by activity changes found
in regions not necessarily damaged in the course of the disease
[15,30]. This evidence opens the possibility that these mechanisms
could mask or protect processes or structures involved in motor
learning, but not necessarily those involved in motor performance.
In conclusion, the current findings show a clear deficit in motor
performance that can be detected years before the clinical onset of
the disease. This motor performance deficit appears before any
motor learning or clinical manifestations of the disease. These
observations identify PC as an objective and quantitative
physiological biomarker that could be of potential use to assess
the efficiency of different therapeutic agents.
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